Screener / SEC EDGAR /CIK 0000873303 /10-K filed Mar 2, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Sarepta Therapeutics, Inc. SRPT

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of SRPT's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Apr 13, 2020
Questions asked 12 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 12 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 2 of 4 closing letter

Half the closed reviews took 2 days or less from the first letter to the closing letter.

Schedule 14A

2020-04-13 to 2020-04-15 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2020-04-15
Restated Certificate Amendment (Proposal 3), page 19
SEC asked
Please revise the proxy statement to indicate whether you currently have any plans, arrangements or understandings, written or oral, to issue any of the authorized but unissued shares that would become available as a result of the amendment to the Restated Certificate.
SRPT answered
to the Staff’s comment, the Company will add the following disclosure under the heading “Restated Certificate Amendment

(Proposal 3)—Purpose and Effect of the Proposal” in its definitive proxy statement on Schedule 14A: “Other than with respect to Proposal 4, the Company has no definitive plan, arrangement, or understanding to issue the additional shares of common stock.”
Read in the reply

Also in this review: closing letter, 2020-04-15

Schedule 14A

2015-04-27 to 2015-04-28 · 1 question · 1 letter from the SEC, 0 from the company
Review closed 2015-04-28
SEC letter of Apr 27, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
SEC asked
Please revise your disclosure in your preliminary proxy statement to discuss whether you have any current plans, agreements, arrangements or understanding with respect to the planned issuance of the newly authorized shares of common and preferred stock. If so, please describe all material terms.
SRPT answered

No reply letter found.

Also in this review: closing letter, 2015-04-28

Form 10-K for the Fiscal Year Ended December 31, 2012

2013-11-25 to 2014-02-13 · 9 questions · 2 letters from the SEC, 3 from the company
No closing letter
Results discussion (MD&A)Debt
Business · Material Agreements and Strategic Alliances, page 12
SEC asked (1)
With respect to each of your July 14, 2010 and August 29, 2012 contracts with the DoD, as well as your November 2012 contract with EU Health Innovation, please disclose:  the relevant intellectual property covered and rights conveyed as to such property;  the duration of the agreement; and  the material termination provisions.
SRPT answered
This letter is to confirm the receipt of your letter dated November 25, 2013 (the “SEC Comment Letter”) regarding the Sarepta Therapeutics, Inc. (the “Company”) filings referenced above. Per your request during our phone conversation on December 12, 2013, the Company believes that it will be able to provide you with a response to the SEC Comment Letter on or before December 24, 2013.
One letter for all the questions, without numbered answers. Read the reply
In its next report

First report after the company's reply of Dec 13, 2013: 10-K filed Mar 3, 2014 ↗, against the 10-K filed Mar 15, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Business · Material Agreements and Strategic Alliances, page 12
SEC asked (2)
Please file the November 2012 contract with EU Health Innovation as an exhibit pursuant to Item 601(b)(10) of Regulation S-K. Alternatively, please provide us with an analysis supporting your determination that such agreement is not material to the company.
SRPT answered

See the reply above.

In its next report

First report after the company's reply of Dec 13, 2013: 10-K filed Mar 3, 2014 ↗, against the 10-K filed Mar 15, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Business · Material Agreements and Strategic Alliances, page 12
SEC asked (3)
Please expand your disclosure of the University of Western Australia (UWA) and Isis agreements, as follows: For your license agreement with the UWA:  describe the terms allowing the parties to terminate the agreement prior to the expiration date; and  disclose how long, at a minimum, the license will remain in effect given the patents currently outstanding For your license agreement with Isis: patents currently
Rest of the question

outstanding.

SRPT answered

See the reply above.

In its next report

First report after the company's reply of Dec 13, 2013: 10-K filed Mar 3, 2014 ↗, against the 10-K filed Mar 15, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Patents and Proprietary Rights, page 15
SEC asked (4)
Please revise your disclosure to include the following information for the patents and patent applications covered by the table on page 16:  the jurisdictions, both foreign and domestic, in which you have patents and patent applications covering the specified product candidates and technology;  clarification whether the patent protection is owned or licensed; and  description of the type of patent protection
Rest of the question

(e.g., method, composition of matter). In addition, please provide the requested information separately for your material patents and patent applications.

SRPT answered

See the reply above.

In its next report

First report after the company's reply of Dec 13, 2013: 10-K filed Mar 3, 2014 ↗, against the 10-K filed Mar 15, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Results of Operations for the years Ended December 31, 2012, 2011 and 2010 · Research and Development Expenses, page 56
SEC asked (5)
Please provide us proposed disclosure to be included in future filings that provides the costs incurred during each period presented and to date for each of your research and development projects discussed on page 4.
SRPT answered

See the reply above.

In its next report

First report after the company's reply of Dec 13, 2013: 10-K filed Mar 3, 2014 ↗, against the 10-K filed Mar 15, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Contractual Payment Obligations, page 59
SEC asked (6)
Please provide us proposed disclosure to be included in future filings to include the interest on long-term debt in the table of contractual obligations. In addition, please revise your note to the table of contractual obligations to include the aggregate amount of potential milestone payments along with a description of the events that would trigger the payments. Notes to Consolidated Financial Statements 9.
Rest of the question

Significant Agreements, page F-21

SRPT answered

See the reply above.

In its next report

First report after the company's reply of Dec 13, 2013: 10-K filed Mar 3, 2014 ↗, against the 10-K filed Mar 15, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Contractual Payment Obligations, page 59
SEC asked (7)
Please provide us proposed disclosure to be included in future filings to include the amount of potential milestone payments you may be required to pay to Isis Pharmaceuticals. Please include the length of and termination provisions for this agreement. Finally, please include disclosure to describe each milestone that Isis may be obligated to make to you and the related contingent consideration.
Rest of the question

Refer to ASC 605-2850-2b.

SRPT answered

See the reply above.

In its next report

First report after the company's reply of Dec 13, 2013: 10-K filed Mar 3, 2014 ↗, against the 10-K filed Mar 15, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Form 10-Q for the quarterly period ended June 30, 2013 · Notes to Condensed Consolidated Financial Statements (Unaudited)
SEC asked (8)
Stock Compensation, page 12 8. You disclose that the method for estimating expected volatility has changed in 2013. Since ASC 718-10-55-40 requires that an entity establish a process for estimating expected volatility and apply that process consistently from period to period, please tell us why you believe it was appropriate to change to the blended estimate.
Rest of the question

Please identify the objective circumstances related either to the availability and reliability of source information that support the change or explain how the new method predicts volatility with greater accuracy. Reference the authoritative literature on which you are relying to change methods. In addition, please tell us how you intend to comply with the disclosure required by ASC 250-10-50-4 regarding this change in estimate.

SRPT answered

See the reply above.

Patents and Proprietary Rights, page 15
SEC asked
We note your response to our prior comment 4 and your proposed additional patent disclosure relating to AVI-7288 and AVI-4658. Please provide similarly expanded disclosure for AVI-7100.
SRPT answered
In response to Staff Comment 1, we plan to include the following disclosure in our next Annual Report on Form 10-K under “Patents and

Proprietary Rights” in substantially the following form:

“Our product candidates and our technology are primarily protected by composition of matter and use patents and patent applications. Currently, our lead clinical product candidates are AVI-4658 (Eteplirsen), AVI-7288 (Marburg) and AVI-7100 (Influenza). We have exclusively licensed patents covering composition of matter and methods of use for AVI-4658 in the United States and Europe.
Rest of the answer

We own issued patents covering composition of matter and methods of use for AVI-7288 in the United States. Additionally, we have pending patent applications for composition of matter and methods of use for AVI-7100 and issued and/ or pending patent applications for composition of matter and methods of use for other product candidates, in the United States, Canada, South America, Europe, Asia, Australia, New Zealand, and/or the Middle East. Patent protection based on currently granted patents and patents granting from currently pending patent applications covering our product candidates and our technology will expire over the following time frames:”

The Company hereby acknowledges that:

•

It is responsible for the adequacy and accuracy of the disclosure in the filing;

The Staff’s comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and

It may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

We hope that the foregoing has been responsive to the Staff’s comments. If you should have any questions about this letter or require any further information, please call the undersigned at 1-857-242-3704 or e-mail at [email protected] with a copy to [email protected]

Respectfully,

Read in the reply
In its next report

First report after the company's reply of Feb 13, 2014: 10-K filed Mar 3, 2014 ↗, against the 10-K filed Mar 15, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: request for more time, Dec 20, 2013, company letter, Jan 6, 2014

Form S-3

2012-03-28 to 2012-08-09 · 1 question · 1 letter from the SEC, 1 from the company
No closing letter
SEC asked
We note that you have a pending confidential treatment request. Please be advised that we will not be in a position to consider a request for acceleration of effectiveness of the registration statement until we resolve all issues concerning the confidential treatment request.
SRPT answered
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 filed on March 21, 2012

(No. 333-180258) (the “Registration Statement”) of Sarepta Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on

August 13, 2012, or as soon as practicable thereafter.
Rest of the answer

Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Kathleen Wells at

(650) 463-2677.

The Company acknowledges that:

• should the Securities and Exchange Commission (the “Commission”) or the staff (the “Staff”) of the Commission, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

the action of the Commission or the Staff, acting pursuant to delegated authority in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
3 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • May 4, 2015 · SRPT: letter to the SEC · Sarepta Therapeutics, Inc. · Post-Effective Amendment No. 3 to · Registration...
  • Apr 28, 2015 · SRPT: letter to the SEC · Sarepta Therapeutics, Inc. · Preliminary Proxy Statement on Schedule 14A · Filed April...
  • Mar 24, 2014 · SEC: letter · Sarepta Therapeutics, Inc. · Form 10-K for the Fiscal Year Ended December 31, 2012 ·...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 16 letters filed since 2012-03-28. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SRPT/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.